$SIBN

SI-BONE, Inc. (SIBN): Entry into a Material Definitive Agreement

SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 11, 2026, SI-BONE, Inc. (the “Company”) and BIXBY SPE FINANCE 11, LLC (“Landlord”) entered into the Fourth Amendment to Lease (the “Fourth Lease Amendment”) to the Office Lease Agreement dated as of February 2, 2

Original reporting
Published Sep 11, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$SIBN
Bearish
medium confidence
Mentioned
$SIBN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SIBNBearishLow
01

Why it matters

The recall introduces a modest cost charge and may raise short‑term quality concerns, while the lease extension has negligible financial effect.

02

Market read

Primary disclosure of a recall and lease amendment; modest impact on SI-BONE's stock price.

03

What to watch

Potential recovery of costs from the tube manufacturer and no impact on revenue.

Relevance 6/10Novelty 6/10Timing: today

Background

SI-BONE filed an 8‑K reporting a lease amendment and a product recall, the first public disclosure of these events.

Company-level read

Ticker impact

$SIBNBearishMedium confidence
Context

SI-BONE disclosed a voluntary recall of 98 iFuse TORQ implants and a lease amendment, estimating up to $150,000 charge to cost of goods sold.

Expected impact

slight dip or flat as investors price in $150k charge

Evidence & confidence

The disclosed charge is small relative to revenue, but recall risk can affect perception of product quality.

Market effects

Medical device sector may see heightened scrutiny on packaging quality.

Limited to U.S. healthcare providers using the product.

Minimal; recall size is small and company is niche.

Counterpoint

The recall cost is negligible; the stock could rebound if the issue is resolved quickly.

Key entities

  • SI-BONE, Inc.

    Medical device manufacturer of spinal implants.

  • BIXBY SPE FINANCE 11, LLC

    Owner of SI-BONE's corporate headquarters lease.

Related articles

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

$SIBNHigh

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance

SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to t